Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ131113131,08
KB105410550,57
PKN89,789,740,44
Msft513,75513,910,06
Nokia4,8934,8992,73
IBM279,88280,24-0,32
Mercedes-Benz Group AG52,2952,32-0,10
PFE24,5724,580,76
16.10.2025 16:07:00
Indexy online
AD Index online
select
AD Index online
 

  • 15.10.2025 11:39:17
Zoetis Inc, Ordinary, New York Consolidated (Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
124,00 -0,67 -0,82 1 612
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 16.10.2025
Popis společnosti

Business Summary: Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Financial Summary: BRIEF: For the six months ended 30 June 2025, Zoetis Inc revenues increased 3% to $4.68B. Net income increased 10% to $1.35B. Revenues reflect US segment increase of 3% to $2.54B, International segment increase of 2% to $2.08B, United States segment increase of 3% to $2.54B, Other Developed segment increase of 11% to $295M. Net income benefited from Selling, General and Administrative Exp decrease of 50% to $563M (expense).



  • Poslední aktualizace: 16.10.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Management Board, Chief Executive OfficerCezary Stypulkowski6805.10.202405.10.2024
Deputy Chairman of the Supervisory BoardBartosz Grzeskowiak-22.04.202422.04.2024
Independent Deputy Chairman of the Supervisory BoardArtur Nowak-Far-22.04.202422.04.2024
Vice President of the Management Board - Supervising the Risk Management DivisionMarcin Gadomski-16.06.202029.11.2019
Vice President of the Management BoardMichal Panowicz-01.09.202501.09.2025
Vice President of the Management Board - Supervising the Operations of the Corporate Banking, Markets and Investment Banking DivRobert Sochacki-09.07.202409.07.2024
Vice President of the Management Board - Supervising the Retail and Private Banking DivisionBlazej Szczecki-15.01.2021
Vice President of the Management Board - Supervising the Operations of the Financial DivisionDagmara Wojnar-18.07.202418.07.2024
Vice President of the Management Board - Supervising the Activities of the Technology and Operations DivisionMarcin Zygmanowski-02.11.202402.11.2024